Evolent Health to Participate in Upcoming Investor Conference
WASHINGTON, July 27, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Chief Executive Officer and Co-Founder Seth Blackley and Chief Financial Officer John Johnson will participate in an upcoming investor conference.
Mr. Blackley and Mr. Johnson will present at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 12:00 p.m. ET. A live webcast will be available on the investor relations section of Evolent's website at http://ir.evolenthealth.com/.
About Evolent Health Evolent Health (NYSE: EVH) delivers proven clinical and administrative solutions that improve whole-person health while making health care simpler and more affordable. Our solutions encompass total cost of care management, specialty care management, and administrative simplification. Evolent serves a national base of leading payers and providers, is the first company to receive the National Committee for Quality Assurance's Population Health Program Accreditation, and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolenthealth.com.
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
First Quarter 2024
Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com.
The earnings release can be found at...
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...